Global Prostate Cancer Diagnosis and Therapy Market Size, Share, Forecast Report, 2020-2027

Prostate Cancer Diagnosis and Therapy Market is expected to register a CAGR of 5.1% to reach USD 18,417.72 Million by 2025.

Prostate cancer is one of the most commonly occurring cancers in men above 55 years of age. More than 80% of the male population are suffering from either one of the prostate cancers (prostatic adenocarcinoma, sarcomas, transitional cell carcinoma, and squamous cell carcinoma) across the globe.

Numerous factors such as a rise in incidence & prevalence rate of prostate cancer, increasing expenditure on oncology medicine research, reimbursements, and favorable health insurance are anticipated to drive the growth of the market during the forecast period. Additionally, poor diet, sedentary lifestyle, genetic factors, smoking & high consumption of alcohol is likely to contribute to the market growth.

The high cost of treatment and side effects hamper the growth of the market. However, the launch of new products acts as opportunities for the growth of the prostate cancer diagnosis and therapy market.

Market Dynamics

Increasing prevalence of prostate cancer is one of the key factors driving market growth. Prostate cancer is the second major cause of death in men and the fourth most commonly occurring cancer. There is an increase in the prevalence of prostate cancer owing to the increasing old age population, obesity, smoking, and poor dietary habits. It is found that people consuming food containing high animal fats and fewer vegetables are more prone to a high risk of prostate cancer. Also, the mutation in genetic material leads to prostate cancer. AGS Health in Aging Foundation, a non-profitable organization, reported that currently, around 3 million American men have either one of prostate cancer such as prostatic adenocarcinoma, sarcomas, transitional cell carcinoma and squamous cell carcinoma.

According to the World Cancer Research Fund UK, there were 1.3 million new cases of prostate cancer reported in 2018 across the globe. France, Ireland, Barbados, Estonia, Norway, and others are some of the top countries with a large number of prostate cancer cases in 2018. Thus, increasing prevalence of cancer across the globe is promoting the demand for various diagnostic and therapeutic methods.
Segmentation

The Global Prostate Cancer Diagnosis and Therapy Market is segmented into Type, Component, and End User. By type, the market has been segmented into prostatic adenocarcinoma, small cell carcinoma and others. Based on product, the market has been segmented into reagents, analyzers, and consumables. Based on the components, the global prostate cancer diagnosis and therapy market have been categorized as therapy and diagnosis. The therapy segment is further is sub-segmented into hormonal therapy, chemotherapy, radiotherapy drugs and immunotherapy. Hormonal therapy is segmented into anti-androgens, LHRH analogs and LHRH antagonists. Chemotherapy is segmented into docetaxel, cabazitaxel and others. The diagnosis is sub-segmented into diagnostic imaging, tissue biopsy, and others.

On the basis of end user, the market has been segmented into specialty centers, hospitals & clinics, and others.
Key Players

The Prominent Players in the Global Prostate Cancer Diagnosis and Therapy Market are Abbvie Inc. (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), Ipsen Pharma (France), Astellas Pharma Inc. (Japan), Johnson & Johnson Services Inc. (US), Tolmar Pharmaceuticals, Inc.(US), Dendreon Pharmaceuticals LLC (US), and Ferring BV (Switzerland), among others.

Market Segmentation

Global Prostate Cancer Diagnosis and Therapy Market, by Type

• Prostatic Adenocarcinoma
• Small Cell Carcinoma
• Others

Global Prostate Cancer Diagnosis and Therapy Market, by Components

Therapy

• Hormonal Therapy
  • ANTI-Androgens
  • LHRH Analogs
  • LHRH Antagonists
• Chemotherapy
  • Docetaxel
  • Cabazitaxel
  • Others
• Radiotherapy Drugs
• Immunotherapy

Diagnosis

• Diagnostic Imaging
• Tissue Biopsy
• Others

Global Prostate Cancer Diagnosis and Therapy Market, by End User

• Specialty Centers
• Hospitals & Clinics
• Others